We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking

By LabMedica International staff writers
Posted on 24 Dec 2021
Print article
Image: LumiraDx SARS-CoV-2 & Flu A/B Antigen Test (Photo courtesy of LumiraDx)
Image: LumiraDx SARS-CoV-2 & Flu A/B Antigen Test (Photo courtesy of LumiraDx)

LumiraDx (London, UK) has achieved CE Marking for its SARS-CoV-2 & Flu A/B Antigen Test.

The microfluidic immunofluorescence assay can quickly verify potential infection for patients suspected of influenza and/or COVID-19, helping to identify and differentiate the underlying cause of respiratory illness and to inform treatment decisions at the point of care. For SARS-CoV-2, the test has a positive percent agreement of up to 95.5% and a negative percent agreement of up to 99.2% versus RT-PCR, based on clinical data collected 0-12 days since symptom onset. For Influenza, the test demonstrated a positive percent agreement of 83.3% (Flu A) and 80% (Flu B) and a negative percent agreement of 97.5% (Flu A) and 95.3% (Flu B) versus RT-PCR, based on retrospective samples collected during 2019-2020 influenza season.

The test's availability comes at a critical time as Europe has entered respiratory illness season, which typically runs November to April, while continuing to deal with increasing rates of COVID-19. The SARS-CoV-2 & Flu A/B Antigen Test helps distinguish between the viral respiratory infections SARS-CoV-2 and influenza while also differentiating between influenza A and influenza B. This is important as the presenting symptoms overlap and guidance of underlying infection is required in determining appropriate interventions and treatments. The detection of SARS-CoV-2, influenza A, and influenza B viral antigen is direct from nasal swab specimens collected from individuals suspected of viral infection consistent with COVID-19 or influenza-like illness by their healthcare provider. Existing respiratory tests on the LumiraDx Platform include the company's SARS-CoV-2 Antigen, SARS-CoV-2 Antibody and SARS-CoV-2 Antigen Pool tests which achieved CE Marking in August 2020, September 2020 and March 2021, respectively.

"Our SARS-CoV-2 & Flu A/B Test builds upon the same microfluidic technology used with our highly sensitive SARS-CoV-2 Ag test which has demonstrated market-leading clinical performance," explained Ron Zwanziger, LumiraDx's Chief Executive Officer. "This season, we are not only experiencing increased rates of COVID-19 with the Omicron variant, but also beginning to see influenza activity throughout the European Region for the first time since the pandemic began. Rapid identification of the underlying cause of respiratory illness is important in guiding appropriate clinical decisions, helping to improve patient outcomes and patient workflows."

Related Links:
LumiraDx

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.